Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
Journal article published in 2011 by
J. Bellmunt,
J. L. González Larriba,
C. Prior,
P. Maroto,
J. Carles,
D. Castellano,
B. Mellado,
E. Gallardo,
J. L. Perez Gracia,
G. Aguilar,
X. Villanueva,
J. Albanell,
A. Calvo 
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 